- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 537
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma
- Interventions
- There is no intervention
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, Myocarditis, ICI-Myocarditis, Solid Malignant Tumor, Hematologic Malignancy, Subclinical Myocarditis, Subclinical ICI-myocarditis
- Interventions
- Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Brown Adipose Tissue
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Stereo Navigator Accessory to PEM Flex PET Scanner
- Device
- Lead sponsor
- Naviscan PET Systems
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • Timonium, Maryland • Portland, Oregon + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- Benfotiamine
- Drug
- Lead sponsor
- Burke Medical Research Institute
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
- Interventions
- pralatrexate, docetaxel, fludeoxyglucose F 18, positron emission tomography
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Myofascial Pain
- Interventions
- 18F-FDG, 11C-butanol
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Breast Cancer, Brain Metastases
- Interventions
- Brain Imaging with 18F-FES
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CT imaging, functional PET imaging
- Other
- Lead sponsor
- Robert Scott Harris, M.D.
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
- Procedure · Other · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
- Interventions
- Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
- Biological · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
- Conditions
- Dose Response Relationship, Drug
- Interventions
- F-18 FDG PET
- Diagnostic Test
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- [F-18]FDG
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Oropharynx Cancer, HPV-Related Carcinoma
- Interventions
- Radiation, Platinum based chemotherapy
- Radiation · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Histologically-confirmed Malignancies
- Interventions
- [18F] FLT, PET/CT scans
- Radiation · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myocardial Infarction, Coronary Artery Disease, Cardiac Catheterization
- Interventions
- PET/CT
- Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 1 Diabetes
- Interventions
- Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- New York, New York
- Conditions
- Lung Disease
- Interventions
- [18F]FDG, [18F]ISO-1
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- CD34 Selected Peripheral Blood Stem Cell Graft
- Interventions
- PET/CT scans, MRI
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, laboratory biomarker analysis, biopsy, F-18 16 alpha-fluoroestradiol, positron emission tomography, anastrozole, letrozole, exemestane, gene expression analysis
- Drug · Other · Procedure + 2 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington